Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)

INTRODUCTION: Multiple sclerosis (MS) patients of African descent have increased risk for disease progression and may be less responsive to disease-modifying therapy. METHODS: Patients in the CARE-MS studies received alemtuzumab 12 mg/day [initial alemtuzumab treatment (IAT); baseline: 5 days; 12 mo...

Full description

Saved in:
Bibliographic Details
Published in:Neurol Ther
Main Authors: Okai, Annette F., Amezcua, Lilyana, Berkovich, Regina R., Chinea, Angel R., Edwards, Keith R., Steingo, Brian, Walker, Aljoeson, Jacobs, Alan K., Daizadeh, Nadia, Williams, Mitzi J.
Format: Artigo
Language:Inglês
Published: Springer Healthcare 2019
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858901/
https://ncbi.nlm.nih.gov/pubmed/31654272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40120-019-00159-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items